Levena Biopharma Co. Ltd. logo

Levena Biopharma Co. Ltd.

Levena BioPharma, is a biotech company focused on developing next generation antibody-drug conjugate therapeutics, targeting cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.levenabiopharma.com
Disease Focus
STOCK CODENon Listed
Address
4955 Directors Place, Suite 300, CA 92121
San Diego
United States
Email
Contact Number
+1 858-203-4200

Levena BioPharma, is a biotech company focused on developing next generation antibody-drug conjugate therapeutics, targeting cancer.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Levena licensed site-specific antibody-drug conjugation technology (C-lock, K-lock) from Concortis Biosystem (now part of Sorrento Therapeutics), along with its proprietary toxin payloads to develop novel antibody-drug conjugate (ADC) therapeutics.

In Dec 2014, Levena BioPharma, signed a collaboration agreement with RC Pharma, a major pharm company in China. Under the terms, Levena will use its site-specific ADC conjugation technology to develop next generation ADC therapeutics with RC Pharma.

In Feb 2015, Levena BioPharma, signed a supply agreement with CSPC pharmaceutical group, a major pharm company in China. Under the agreement, Levena will supply toxin, linker-toxin to support CSPCs ADC programs for the next 3 years.